ReviewWorld journal of gastroenterology2016
MicroRNAs: Novel immunotherapeutic targets in colorectal carcinoma.
Review in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Non-Coding RNAs Implicated in the Tumor Microenvironment of Colorectal Cancer: Roles, Mechanisms and Clinical Study.Frontiers in oncology · 2022Pooled it
- The Preliminary Study for the Trial of Using Selected miRNAs for the Laboratory Diagnosis of Colorectal Cancer.International journal of molecular sciences · 2026Article
- MiR-200a regulates PD-L1 and predicts response to immune checkpoint inhibitors in advanced non-small cell lung cancer.Translational lung cancer research · 2025Article
- A comprehensive review on RNA interference-mediated targeting of interleukins and its potential therapeutic implications in colon cancer.3 Biotech · 2023Review
- Molecular Mechanisms of Tumor Immunomodulation in the Microenvironment of Colorectal Cancer.International journal of molecular sciences · 2022Review
- Circular RNA, hsa_circRNA_102049, promotes colorectal cancer cell migration and invasion via binding and suppressing miRNA-455-3p.Experimental and therapeutic medicine · 2022Article
- Establishment and experimental validation of an immune miRNA signature for assessing prognosis and immune landscape of patients with colorectal cancer.Journal of cellular and molecular medicine · 2021Article
- MicroRNA-146a limits tumorigenic inflammation in colorectal cancer.Nature communications · 2021Article
- GRHL3 Promotes Tumor Growth and Metastasis via the MEK Pathway in Colorectal Cancer.Analytical cellular pathology (Amsterdam) · 2021Article
- Article
- What could microRNA expression tell us more about colorectal serrated pathway carcinogenesis?World journal of gastroenterology · 2020Review
- HDAC inhibitors promote pancreatic stellate cell apoptosis and relieve pancreatic fibrosis by upregulating miR-15/16 in chronic pancreatitis.Human cell · 2020Article
- Mast Cells, microRNAs and Others: The Role of Translational Research on Colorectal Cancer in the Forthcoming Era of Precision Medicine.Journal of clinical medicine · 2020Review
- Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors.Biomolecules · 2020Review
- miR-22 Suppresses Tumor Invasion and Metastasis in Colorectal Cancer by Targeting NLRP3.Cancer management and research · 2020Article
- Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies.Frontiers in cell and developmental biology · 2020Review
- Novel Biomarkers for Personalized Cancer Immunotherapy.Cancers · 2019Review
- MicroRNA‑3666 suppresses the growth and migration of glioblastoma cells by targeting KDM2A.Molecular medicine reports · 2019Article
- MiR-4524b-5p/WTX/β-catenin axis functions as a regulator of metastasis in cervical cancer.PloS one · 2019Article
- Relationship betweenWorld journal of gastroenterology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal carcinoma (CRC) is one of the most common types of cancer worldwide and the prognosis for CRC patients with recurrence or metastasis is extremely poor. Although chemotherapy and radiation therapy can improve survival, there are still numerous efforts to be performed. Immunotherapy is frequently used, either alone or in combination with other therapies, for the treatment of CRC and is a safe and feasible way to improve CRC treatment. Furthermore, the significance of the immune system in the biology of CRC has been demonstrated by retrospective assessments of immune infiltrates in resected CRC tumors. MicroRNAs (miRNAs) are short, non-coding RNAs that can regulate multiple target genes at the post-transcriptional level and play critical roles in cell proliferation, differentiation and apoptosis. MiRNAs are required for normal immune system development and function. Nevertheless, aberrant expression of miRNAs is often observed in various tumor types and leads to immune disorders or immune evasion. The immunomodulatory function of miRNAs indicates that miRNAs may ultimately be part of the portfolio of anti-cancer targets. Herein, we will review the potential roles of miRNAs in the regulation of the immune response in CRC and then move on to discuss how to utilize different miRNA targets to treat CRC. We also provide an overview of the major limitations and challenges of using miRNAs as immunotherapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.